Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.43 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13316750 | 0.85 | ESR1 (0.42) | ESR1ESR2HSD17B3MCL1PTGES | |
| SCHEMBL12856652 | 0.79 | ESR1 (0.41) | ESR1ESR2HSD17B3MCL1PTGES | |
| SCHEMBL23322803 | 0.77 | CYP1A2 (0.50) | CYP1A2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2209442 | 0.76 | ESR1 (0.58) | ESR1ESR2MCL1CYP1A2TLR8 | |
| SCHEMBL29771841 | 0.76 | ESR1 (0.58) | ESR1ESR2MCL1CYP1A2TLR8 | |
| SCHEMBL9623383 | 0.76 | ESR2 (0.52) | ESR1ESR2MCL1CYP1A2TLR8 | |
| SCHEMBL12912891 | 0.75 | ESR1 (0.46) | ESR1ESR2HSD17B3MCL1PTGES | |
| SCHEMBL29276380 | 0.75 | CYP1A2 (0.45) | ESR2HSD17B3MCL1CYP1A2KDM4E | |
| SCHEMBL2046089 | 0.74 | ESR1 (0.52) | ESR1ESR2HSD17B3MCL1CYP1A2 | |
| SCHEMBL806516 | 0.74 | CYP1A2 (0.54) | ESR1ESR2MCL1PTGESCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8303844-B2 | Benzo[f]chrome any pyrano[3,2-f]chrome derivatives for use in liquid crystal media | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-11-06 | — | — | US | disclosed |
| WO-2012036253-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-22 | — | — | WO | disclosed |
| US-20110043746-A1 | BENZO[F]CHROME ANY PYRANO[3,2-F]CHROME DERIVATIVES FOR USE IN LIQUID CRYSTAL MEDIA | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110043746-A1 | BENZO[F]CHROME ANY PYRANO[3,2-F]CHROME DERIVATIVES FOR USE IN LIQUID CRYSTAL MEDIA | CHRM1, F12, CTRB2 | ESR1 360/4885ESR2 589/4885HSD17B3 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.